– Invitae launches seamless digital platform to enhance patient
and provider experiences and further bring genetics to mainstream
medicine –
SAN
FRANCISCO, March 29, 2022 /PRNewswire/ -- Invitae
(NYSE: NVTA), a leading medical genetics company, today announced
the launch of Invitae Digital Health—a connected digital health
platform that informs health decisions through actionable genomic
insights for patients and clinicians.
With Invitae Digital Health, healthcare providers and health
systems engage with a single, seamless platform that integrates
important health data throughout each patient's lifetime. Rooted in
genetic insights and scalable at the population level, it will
enable a holistic approach to personalized health management for
individuals throughout their health journey.
Ushering in a new era of proactive healthcare
With
19.3 million new cases of cancer worldwide in 2020, 420 million
cases of cardiovascular disease2, 8 million children
born with a serious genetic condition each year
worldwide3, and 99% of people with genetic
variation that can impact drug response4, the
potential impact of genetics on mainstream healthcare is
profound.
A modular platform tailored to the needs of health systems and
their patients, Invitae Digital Health will encourage healthcare
providers to move away from the traditional reactive healthcare
model and toward a new era of proactive, population-based care. By
enabling the identification of disease risk earlier in the care
continuum, the platform is poised to help providers and patients
enhance early detection and better personalize treatments with the
goals of achieving better outcomes and reducing the burden on the
broader healthcare system.
"Invitae has completed more than six software acquisitions since
2019 with a vision for a unified platform that can surface
actionable genomic information to help keep large populations
healthy or better manage disease," said Kamal Gogineni, President, Digital Health at
Invitae. "The next step is Invitae Digital Health, a personalized
health management platform at the intersection of genetics and real
world clinical data. Its launch cements Invitae's commitment to
advance medicine to benefit both patients and
clinicians."
While existing population health solutions are positioned for
point-of-care oncology testing only, Invitae Digital Health brings
genomics to mainstream medicine across a broad spectrum of places
where care is impacted—cardiology, medication management through
pharmacogenomics, rare disease, neurology, pediatrics, women's
health and oncology (both pre- and post-diagnosis).
"Invitae Digital Health is designed to synthesize and humanize
clinical and genetic information to empower individuals and their
care teams to make informed health decisions," said Rakesh Patel, M.D., Chief Medical Officer,
Digital Health at Invitae. "We're proud to be delivering upon a
much-needed solution that we hope will propel forward the use of
genetic insights in mainstream medicine."
Modular suite of tools for health systems to customize
workflows
Invitae Digital Health will provide healthcare
systems with a fully-integrated, customizable suite of tools in a
single, intuitive platform. Capabilities include:
- Seamless integrations with electronic health record
solutions
- Clinical decision support to help clinicians determine which
patients should receive genetic testing or supplemental
imaging
- Utilization of medical management guidelines, which are
continuously updated to remain current
- Scalable and secure data-exchange using industry standard
protocols
"Invitae Digital Health will be a powerful conduit to allow
healthcare systems to deliver proactive healthcare, which is
crucial as disease rates rise and hospitals remain overburdened,"
said Burns C. Blaxall, Ph.D., Executive Director of Precision
Medicine at The Christ Hospital Health Network. "As genomics moves
into mainstream medicine, providers need to easily know who to
test, what test to order, and how to act on that information based
on the latest evidence both now and in the future—and Invitae
Digital Health is making this possible across multiple clinical
areas."
Healthcare providers can learn more about Invitae Digital Health
here.
______________
1 ACS publication from International Agency for
Research on Cancer: Sung, H, Ferlay, J, Siegel, RL, Laversanne, M,
Soerjomataram, I, Jemal, A, Bray,
F. Global cancer statistics
2 Roth GA, Johnson C, Abajobir A, et al. Global,
regional, and national burden of cardiovascular diseases for 10
causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
3 March of Dimes. Global report on birth defects.
2006.
4 McInnesG, et al. Clin Pharmacol Ther.
2021;109(6):1528–1537
5 Haverfield EV et al. Physician-directed genetic
screening to evaluate personal risk for medically actionable
disorders: a large multi-center cohort study. BMC Med. 2021 Aug
18;19(1):199. doi: 10.1186/s12916-021-01999-2
About Invitae
Invitae Corporation (NYSE: NVTA) is a
leading medical genetics company, whose mission is to bring
comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time and lower prices. For more
information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the availability, features and potential impact of
Invitae Digital Health; the company's beliefs regarding the
potential impact of genetics on mainstream medicine; the company's
beliefs that Invitae Digital Health will encourage healthcare
providers to move toward a new era of proactive, population-based
care; and the company's beliefs that Invitae Digital Health can
help enhance early detection and better personalize treatments with
the goals of achieving better outcomes and reducing the burden on
the broader healthcare system. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially,and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the company's
history of losses; the company's ability to compete; the company's
failure to manage growth effectively; the company's need to scale
its infrastructure in advance of demand for its tests and to
increase demand for its tests; the company's ability to use rapidly
changing genetic data to interpret test results accurately and
consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Annual Report on Form 10-K for the year
ended December 31, 2021. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Contact:
Amy Hadsock
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/introducing-invitae-digital-healtha-personalized-health-management-platform-that-leverages-genomic-insights-to-inform-health-decisions-for-patients-and-clinicians-301511876.html
SOURCE Invitae Corporation